2012-2633. New Animal Drugs; Change of Sponsor; Chlortetracycline Powder  

  • Start Preamble Start Printed Page 5700

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Final rule.

    SUMMARY:

    The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for an abbreviated new animal drug application (ANADA) for chlortetracycline soluble powder from Teva Animal Health, Inc., to Quo Vademus, LLC.

    DATES:

    This rule is effective February 6, 2012.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Steven D. Vaughn, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7520 Standish Pl., Rockville, MD 20855, (240) 276-8300, email: steven.vaughn@fda.hhs.gov.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    Teva Animal Health, Inc., 3915 South 48th Street Ter., St. Joseph, MO 64503, has informed FDA that it has transferred ownership of, and all rights and interest in, ANADA 200-236 for Chlortetracycline HCL Soluble Powder to Quo Vademus, LLC, 277 Faison McGowan Rd., Kenansville, NC 28349. Accordingly, the Agency is amending the regulations in 21 CFR 520.441 to reflect the transfer of ownership.

    Quo Vademus, LLC, is not currently listed in the animal drug regulations as a sponsor of an approved application. Accordingly, 21 CFR 510.600 is being amended to add entries for this sponsor.

    This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

    Start List of Subjects

    List of Subjects

    21 CFR Part 510

    • Administrative practice and procedure
    • Animal drugs
    • Labeling
    • Reporting and recordkeeping requirements

    21 CFR Part 520

    • Animal drugs
    End List of Subjects

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 520 are amended as follows:

    Start Part

    PART 510—NEW ANIMAL DRUGS

    End Part Start Amendment Part

    1. The authority citation for 21 CFR part 510 continues to read as follows:

    End Amendment Part Start Authority

    Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

    End Authority Start Amendment Part

    2. In § 510.600, in the table in paragraph (c)(1), alphabetically add a new entry for “Quo Vademus, LLC”; and in the table in paragraph (c)(2), in numerical sequence add a new entry for “076475” to read as follows:

    End Amendment Part
    Names, addresses, and drug labeler codes of sponsors of approved applications.
    * * * * *

    (c) * * *

    (1) * * *

    Firm name and addressDrug labeler code
    *    *    *    *    *    
    Quo Vademus, LLC, 277 Faison McGowan Rd., Kenansville, NC 28349076475
    *    *    *    *    *    

    (2) * * *

    Drug labeler codeFirm name and address
    *    *    *    *    *    
    076475Quo Vademus, LLC, 277 Faison McGowan Rd., Kenansville, NC 28349
    *    *    *    *    *    
    Start Part

    PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

    End Part Start Amendment Part

    3. The authority citation for 21 CFR part 520 continues to read as follows:

    End Amendment Part Start Authority

    Authority: 21 U.S.C. 360b.

    End Authority
    [Amended]
    Start Amendment Part

    4. In paragraph (b)(4) of § 520.441, remove “059130” and in its place add “076475”.

    End Amendment Part Start Signature

    Dated: February 1, 2012.

    William T. Flynn,

    Acting Director, Center for Veterinary Medicine.

    End Signature End Supplemental Information

    [FR Doc. 2012-2633 Filed 2-3-12; 8:45 am]

    BILLING CODE 4160-01-P